Efficacy of postprocedural anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction

A post-hoc analysis of the randomized INNOVATION trial

Pil Sang Song, Min Jeong Kim, Ki Hyun Jeon, Sungmin Lim, Jin Sik Park, Rak Kyeong Choi, Je Sang Kim, Hyun Jong Lee, Tae Hoon Kim, Young Jin Choi, Do-Sun Lim, Cheol Woong Yu

Research output: Contribution to journalArticle

Abstract

There exists controversy on whether and for how long anticoagulation is necessary after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).We aimed to study the impact of prolonged (>24 h) or brief (<24 h) postprocedural anticoagulation on infarct size assessed by cardiac magnetic resonance (CMR) after 30 days as well as on left ventricular ejection fraction (LVEF) and left ventricular (LV) remodeling evaluated by 2D-echocardiography after 9 months from the INNOVATION trial (Clinical Trial Registration: NCT02324348).Of the 114 patients (mean age: 59.5 years) enrolled, 76 (66.7%) received prolonged anticoagulation therapy (median duration: 72.6 h) and 38 (33.3%) patients received brief anticoagulation therapy (median duration: 5 h) after primary PCI. There was no significant difference in infarct size (mean size: 15.6% after prolonged anticoagulation versus 19.8% after brief anticoagulation, P = .100) and the incidence of microvascular obstruction (50.7% versus 52.9%, P = .830) between the groups. Even after adjusting, prolonged anticoagulation therapy could not reduce larger infarct (defined as >75 percentile of infarct size; 19.7% versus 35.3%; adjusted odd ratio [OR]: 0.435; 95% confidence interval [CI]: 0.120-1.57; P = .204). Similar results were observed in subanalyses of major high-risk subgroups. Moreover, follow-up LVEF <35% (3.2% versus 7.4%; adjusted OR: 0.383; 95% CI: 0.051-2.884; P = .352) and LV remodeling (defined as >20% increase in LV end-diastolic volume; 37.1% versus 18.5%; adjusted OR: 2.249; 95% CI: 0.593-8.535; P = .234) were similar between groups.These data suggest that prolonged postprocedural anticoagulation may not provide much benefit after successful primary PCI in patients with STEMI. However, further studies are needed.

Original languageEnglish
Pages (from-to)e15277
JournalMedicine
Volume98
Issue number17
DOIs
Publication statusPublished - 2019 Apr 1

Fingerprint

Percutaneous Coronary Intervention
Odds Ratio
Confidence Intervals
Myocardial Infarction
ST Elevation Myocardial Infarction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of postprocedural anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction : A post-hoc analysis of the randomized INNOVATION trial. / Song, Pil Sang; Kim, Min Jeong; Jeon, Ki Hyun; Lim, Sungmin; Park, Jin Sik; Choi, Rak Kyeong; Kim, Je Sang; Lee, Hyun Jong; Kim, Tae Hoon; Choi, Young Jin; Lim, Do-Sun; Yu, Cheol Woong.

In: Medicine, Vol. 98, No. 17, 01.04.2019, p. e15277.

Research output: Contribution to journalArticle

Song, Pil Sang ; Kim, Min Jeong ; Jeon, Ki Hyun ; Lim, Sungmin ; Park, Jin Sik ; Choi, Rak Kyeong ; Kim, Je Sang ; Lee, Hyun Jong ; Kim, Tae Hoon ; Choi, Young Jin ; Lim, Do-Sun ; Yu, Cheol Woong. / Efficacy of postprocedural anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction : A post-hoc analysis of the randomized INNOVATION trial. In: Medicine. 2019 ; Vol. 98, No. 17. pp. e15277.
@article{cfcb8cf689f64ad59c125f921340426e,
title = "Efficacy of postprocedural anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A post-hoc analysis of the randomized INNOVATION trial",
abstract = "There exists controversy on whether and for how long anticoagulation is necessary after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).We aimed to study the impact of prolonged (>24 h) or brief (<24 h) postprocedural anticoagulation on infarct size assessed by cardiac magnetic resonance (CMR) after 30 days as well as on left ventricular ejection fraction (LVEF) and left ventricular (LV) remodeling evaluated by 2D-echocardiography after 9 months from the INNOVATION trial (Clinical Trial Registration: NCT02324348).Of the 114 patients (mean age: 59.5 years) enrolled, 76 (66.7{\%}) received prolonged anticoagulation therapy (median duration: 72.6 h) and 38 (33.3{\%}) patients received brief anticoagulation therapy (median duration: 5 h) after primary PCI. There was no significant difference in infarct size (mean size: 15.6{\%} after prolonged anticoagulation versus 19.8{\%} after brief anticoagulation, P = .100) and the incidence of microvascular obstruction (50.7{\%} versus 52.9{\%}, P = .830) between the groups. Even after adjusting, prolonged anticoagulation therapy could not reduce larger infarct (defined as >75 percentile of infarct size; 19.7{\%} versus 35.3{\%}; adjusted odd ratio [OR]: 0.435; 95{\%} confidence interval [CI]: 0.120-1.57; P = .204). Similar results were observed in subanalyses of major high-risk subgroups. Moreover, follow-up LVEF <35{\%} (3.2{\%} versus 7.4{\%}; adjusted OR: 0.383; 95{\%} CI: 0.051-2.884; P = .352) and LV remodeling (defined as >20{\%} increase in LV end-diastolic volume; 37.1{\%} versus 18.5{\%}; adjusted OR: 2.249; 95{\%} CI: 0.593-8.535; P = .234) were similar between groups.These data suggest that prolonged postprocedural anticoagulation may not provide much benefit after successful primary PCI in patients with STEMI. However, further studies are needed.",
author = "Song, {Pil Sang} and Kim, {Min Jeong} and Jeon, {Ki Hyun} and Sungmin Lim and Park, {Jin Sik} and Choi, {Rak Kyeong} and Kim, {Je Sang} and Lee, {Hyun Jong} and Kim, {Tae Hoon} and Choi, {Young Jin} and Do-Sun Lim and Yu, {Cheol Woong}",
year = "2019",
month = "4",
day = "1",
doi = "10.1097/MD.0000000000015277",
language = "English",
volume = "98",
pages = "e15277",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "17",

}

TY - JOUR

T1 - Efficacy of postprocedural anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction

T2 - A post-hoc analysis of the randomized INNOVATION trial

AU - Song, Pil Sang

AU - Kim, Min Jeong

AU - Jeon, Ki Hyun

AU - Lim, Sungmin

AU - Park, Jin Sik

AU - Choi, Rak Kyeong

AU - Kim, Je Sang

AU - Lee, Hyun Jong

AU - Kim, Tae Hoon

AU - Choi, Young Jin

AU - Lim, Do-Sun

AU - Yu, Cheol Woong

PY - 2019/4/1

Y1 - 2019/4/1

N2 - There exists controversy on whether and for how long anticoagulation is necessary after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).We aimed to study the impact of prolonged (>24 h) or brief (<24 h) postprocedural anticoagulation on infarct size assessed by cardiac magnetic resonance (CMR) after 30 days as well as on left ventricular ejection fraction (LVEF) and left ventricular (LV) remodeling evaluated by 2D-echocardiography after 9 months from the INNOVATION trial (Clinical Trial Registration: NCT02324348).Of the 114 patients (mean age: 59.5 years) enrolled, 76 (66.7%) received prolonged anticoagulation therapy (median duration: 72.6 h) and 38 (33.3%) patients received brief anticoagulation therapy (median duration: 5 h) after primary PCI. There was no significant difference in infarct size (mean size: 15.6% after prolonged anticoagulation versus 19.8% after brief anticoagulation, P = .100) and the incidence of microvascular obstruction (50.7% versus 52.9%, P = .830) between the groups. Even after adjusting, prolonged anticoagulation therapy could not reduce larger infarct (defined as >75 percentile of infarct size; 19.7% versus 35.3%; adjusted odd ratio [OR]: 0.435; 95% confidence interval [CI]: 0.120-1.57; P = .204). Similar results were observed in subanalyses of major high-risk subgroups. Moreover, follow-up LVEF <35% (3.2% versus 7.4%; adjusted OR: 0.383; 95% CI: 0.051-2.884; P = .352) and LV remodeling (defined as >20% increase in LV end-diastolic volume; 37.1% versus 18.5%; adjusted OR: 2.249; 95% CI: 0.593-8.535; P = .234) were similar between groups.These data suggest that prolonged postprocedural anticoagulation may not provide much benefit after successful primary PCI in patients with STEMI. However, further studies are needed.

AB - There exists controversy on whether and for how long anticoagulation is necessary after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).We aimed to study the impact of prolonged (>24 h) or brief (<24 h) postprocedural anticoagulation on infarct size assessed by cardiac magnetic resonance (CMR) after 30 days as well as on left ventricular ejection fraction (LVEF) and left ventricular (LV) remodeling evaluated by 2D-echocardiography after 9 months from the INNOVATION trial (Clinical Trial Registration: NCT02324348).Of the 114 patients (mean age: 59.5 years) enrolled, 76 (66.7%) received prolonged anticoagulation therapy (median duration: 72.6 h) and 38 (33.3%) patients received brief anticoagulation therapy (median duration: 5 h) after primary PCI. There was no significant difference in infarct size (mean size: 15.6% after prolonged anticoagulation versus 19.8% after brief anticoagulation, P = .100) and the incidence of microvascular obstruction (50.7% versus 52.9%, P = .830) between the groups. Even after adjusting, prolonged anticoagulation therapy could not reduce larger infarct (defined as >75 percentile of infarct size; 19.7% versus 35.3%; adjusted odd ratio [OR]: 0.435; 95% confidence interval [CI]: 0.120-1.57; P = .204). Similar results were observed in subanalyses of major high-risk subgroups. Moreover, follow-up LVEF <35% (3.2% versus 7.4%; adjusted OR: 0.383; 95% CI: 0.051-2.884; P = .352) and LV remodeling (defined as >20% increase in LV end-diastolic volume; 37.1% versus 18.5%; adjusted OR: 2.249; 95% CI: 0.593-8.535; P = .234) were similar between groups.These data suggest that prolonged postprocedural anticoagulation may not provide much benefit after successful primary PCI in patients with STEMI. However, further studies are needed.

UR - http://www.scopus.com/inward/record.url?scp=85065341235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065341235&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000015277

DO - 10.1097/MD.0000000000015277

M3 - Article

VL - 98

SP - e15277

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 17

ER -